Research output per year
Research output per year
Fingerprint
Dive into the research topics where Alexandra Zimmer is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial
Khoury, K., Meisel, J. L., Yau, C., Rugo, H. S., Nanda, R., Davidian, M., Tsiatis, B., Chien, A. J., Wallace, A. M., Arora, M., Rozenblit, M., Hershman, D. L., Zimmer, A., Clark, A. S., Beckwith, H., Elias, A. D., Stringer-Reasor, E., Boughey, J. C., Nangia, C. & Vaklavas, C. & 37 others, , Dec 2024, In: Nature medicine. 30, 12, p. 3728-3736 9 p., 63.Research output: Contribution to journal › Article › peer-review
2 Scopus citations -
Initial experience in implementing quantitative DCE-MRI to predict breast cancer therapy response in a multi-center and multi-vendor platform setting
Moloney, B., Li, X., Hirano, M., Saad Eddin, A., Lim, J. Y., Biswas, D., Kazerouni, A. S., Tudorica, A., Li, I., Bryant, M. L., Wille, C., Pyle, C., Rahbar, H., Hsieh, S. K., Rice-Stitt, T. L., Dintzis, S. M., Bashir, A., Hobbs, E., Zimmer, A. & Specht, J. M. & 5 others, , 2024, In: Frontiers in Oncology. 14, 1395502.Research output: Contribution to journal › Article › peer-review
Open Access -
A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
Atkins, S. L. P., Greer, Y. E., Jenkins, S., Gatti-Mays, M. E., Houston, N., Lee, S., Lee, M. J., Rastogi, S., Sato, N., Burks, C., Annunziata, C. M., Lee, J. M., Nagashima, K., Trepel, J. B., Lipkowitz, S. & Zimmer, A. S., Oct 2023, In: Oncologist. 28, 10, p. E919-E972Research output: Contribution to journal › Article › peer-review
Open Access4 Scopus citations -
Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors (Journal of Experimental & Clinical Cancer Research, (2023), 42, 1, (76), 10.1186/s13046-023-02649-6)
Cole, C. B., Morelli, M. P., Fantini, M., Miettinen, M., Fetsch, P., Peer, C., Figg, W. D., Yin, T., Houston, N., McCoy, A., Lipkowitz, S., Zimmer, A., Lee, J. M., Pavelova, M., Villanueva, E. N., Trewhitt, K., Solarz, B. B., Fergusson, M., Mavroukakis, S. A. & Zaki, A. & 3 others, , Dec 2023, In: Journal of Experimental and Clinical Cancer Research. 42, 1, 102.Research output: Contribution to journal › Comment/debate › peer-review
Open Access1 Scopus citations -
First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors
Cole, C. B., Morelli, M. P., Fantini, M., Miettinen, M., Fetsch, P., Peer, C., Figg, W. D., Yin, T., Houston, N., McCoy, A., Lipkowitz, S., Zimmer, A., Lee, J. M., Pavelova, M., Villanueva, E. N., Trewhitt, K., Solarz, B. B., Fergusson, M., Mavroukakis, S. A. & Zaki, A. & 3 others, , Dec 2023, In: Journal of Experimental and Clinical Cancer Research. 42, 1, 76.Research output: Contribution to journal › Article › peer-review
Open Access9 Scopus citations